|Bid||0.00 x 900|
|Ask||0.00 x 4000|
|Day's Range||30.07 - 30.26|
|52 Week Range||28.82 - 31.85|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.
GlaxoSmithKline (GSK) reported revenues of ~7.2 billion pounds for 1Q18 on April 25, a ~2% decline from its ~7.3 billion pounds in 1Q17. This change includes 4% growth in revenues at constant exchange rates, offset by a 6% decrease in revenues due to the negative impact of foreign exchange. The company’s stock is listed on the London Stock Exchange, and the company reports its financial statements in pounds sterling. GlaxoSmithKline reported revenues of ~7.2 billion in 1Q18, a ~2% decline from its revenues of ~7.3 billion pounds in 1Q17. ...
As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.
Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
Headquartered in Basel, Switzerland, Novartis (NVS) is one of the largest pharmaceutical companies by revenue. Novartis specializes in the development, manufacturing, and marketing of healthcare products.
Novartis AG (NVS) announced an agreement and plan for a merger with AveXis on April 9, 2018. Following the recovery of major US indexes after the US-China trade war concerns—and also due to the announcement of the acquisition—Novartis AG’s ADR (American depositary receipt) reported a 1.1% rise in its price to close at $81.07 on April 9 compared to its previous close of $80.20 on April 6.
As we’ve already seen, Johnson & Johnson reported revenues of ~$20.2 billion in 4Q17, an 11.5% growth in revenues compared to ~$18.1 billion in 4Q16. Analysts also estimate that Johnson & Johnson could generate EPS (earnings per share) of $2.01 on revenues of ~$19.4 billion in 1Q18, a 9.2% growth compared to 1Q17. Analyst recommendations show a 12-month target price of $150.62 per share compared to its last price of $132.02 per share on February 23, 2018.
First Trust has come a long way since its foray into the exchange traded fund universe more than a decade ago.
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros. Ablynx and Sanofi had a successful existing partnership for multiple sclerosis research and immunoinflammatory diseases. Under the agreement terms, Sanofi gained access Ablynx’s scientists, certain nanobodies in its product portfolio, and Ablynx’s proprietary nanobody platform.
GlaxoSmithKline (GSK) estimates the global incidence of MM to be close to 124,000 with 30,000 patients in the US, 27,000 in EU5, and around 8,000 in Japan. The above diagram shows that despite the advent of multiple new treatment options from companies like Celgene (CELG), Johnson & Johnson (JNJ), and Amgen (AMGN), the five-year survival rate for MM patients continues to be below 50%. In 2016, the global market value of MM was around $12 billion, a year-over-year (or YoY) rise of 40%.
In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.
Income investors looking for stocks that have achieved dividend achievers status do not need to confine their search to large-cap equities. A new exchange traded fund from First Trust provides a basket ...
This series will discuss the top ten aerospace and defense products and services companies based on their dividend yields.
First Trust Advisors L.P. announces the declaration of distributions for 116 exchange-traded funds advised by FTA.
In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.